"AbbVie Says Upadacitinib Met Primary Endpoint In Phase 2B Study In Atopic Dermatitis"
AbbVie, a global research and development based Biopharmaceutical Company announced positive top-line results from the Phase 2b randomized, placebo-controlled, dose-ranging study of upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis not adequately controlled by topical treatments, or for whom topical treatments were not medically advisable. "Atopic dermatitis is a serious, chronic skin disease that can have a negative impact on patients' lives," said lead study investigator, Emma Guttman-Yassky, MD, PhD, professor of dermatology, clinical immunology, and medicine at the Icahn School of Medicine at Mount Sinai. "I am very encouraged that itch reduction was achieved within the first week and that up to half of patients achieved a 90 percent or more improvement in skin lesions by week 16. These are both major concerns for patients with atopic dermatitis. With these results upadacitinib has the potential to be an important treatment option for patients,” Dr. Guttman-Yassky added.
- Emma Guttman-Yassky, MD, PhD, Professor, Dermatology, Clinical Immunology, Medicine, Icahn School of Medicine at Mount Sinai
